Copyright © Inderes 2011 - present. All rights reserved.

Bioretec

0.30 EUR

0.00 %

1,717 following
Corporate customer

BRETEC

First North Finland

Medical Equipment & Services

Health Care

0.00 %
-42.41 %
-50.67 %
-65.66 %
-77.74 %
-87.49 %
-90.19 %
-
-89.49 %

Bioretec operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio includes, for example, implants for pediatric and adult orthopedics and other materials for bone and soft tissue injuries. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in the Nordic region.

Read more
Market cap
9.11M EUR
Turnover
30.92K EUR
P/E (adj.) (26e)
-3.38
EV/EBIT (adj.) (26e)
-2.75
P/B (26e)
2.02
EV/S (26e)
5.09
Dividend yield-% (26e)
-
Coverage
Recommendation
Accumulate
Target price
0.32 EUR
Updated
2026-02-15
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 2026-02-16

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
8/5
2026

General meeting '26

14/5
2026

Business review Q1'26

13/8
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
I watched the Hubar - Fisher “interview.” It was a complete nothing-burger. He got the opportunity to answer (likely) a few selected questions that brought zero added value or clarified anything. At least not for yours truly. Not a single difficult question was asked, and I bet there...
2/13/2026, 1:17 PM
by Balle Ramsted - pienehkö kasvusijoittaja nupullaan
14
Has it occurred to anyone that perhaps the product isn’t as great as the company suggests and shareholders want to believe? I, at least, have formed the impression that because the screw contains zinc and calcium in addition to magnesium, the screw doesn’t suffer from the same hydrogen...
2/13/2026, 11:32 AM
by Osakepoimija
9
And so, those regulatory approvals like FDA and CE don’t really mean anything commercially (cf. CE-marked Christmas lights that caught fire), but they are a prerequisite for making progress. On the other hand, for example, 17 VAC approvals is quite a positive development (Sarah has...
2/14/2026, 9:06 AM
by Roope Joskus
8
Sarah’s interview was definitely devoid of substance. In a way, she made the right points and critical observations (like how Remeo requires country-specific registrations in the EU for everything, even the instruments used to install implants), but it felt like she just wanted to...
2/13/2026, 6:07 PM
by Haminan Mursu
8
Siltanen has been working hard on Sunday evening to complete a new company report on Bioretec following its Q4 results. Bioretec’s end to the year fell short of our forecasts. During 2025, the company has been rebuilding its commercial foundation and is aiming to restore dented investor...
2/15/2026, 8:35 PM
by Sijoittaja-alokas
7
No sharp reaction or growth is visible yet. To my eyes, it seems that they have finally rolled up their sleeves, but fixing previous dawdling is happening painfully slowly. In my investment case, the need for additional funding was the expected outcome. I’m not dumping my shares ...
2/14/2026, 11:57 AM
by Optimistinen verkkapöksy
7
In the webcast, they provided assurances that demand is growing and that they are leaders in their field, with others also entering the market. Applications are pending in several countries where CE marking is recognized. Permits are also required for tools—drills, screwdrivers, ...
2/13/2026, 11:32 AM
by Vino Pino
7
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.